According to iData, the European market will grow throughout the forecast period due to demographic factors, the prevalence of obesity, and clinical proof.
Exclusive study on the European orthopedic biomaterials industry has been provided by iData Research ("iData"), a multinational consultancy and market research business. The orthopedic biomaterials market is highly variable among the 15 European nations studied, and different national rules and reimbursement schemes have a significant impact. The European market will rise throughout the projection period, according to iData, due to demographic considerations and the prevalence of obesity, as well as clinical proof.
The European market for orthopedic biomaterials was previously estimated at roughly €500 million, according to iData's EU Report for Orthopedic Biomaterials. Furthermore, the market has continued to grow in 2021 and 2022, with a projected value of nearly €582 million by 2025. Similarly, by 2025, the number of orthopedic biomaterial treatments performed per country is expected to double. Procedure statistics, unit sales, average selling prices, market drivers and limiters, competitive market share analysis, and more are included in this study.
Among the many rivals in these markets, the European leaders are Fidia, Medtronic, and TRB Chemedica, followed by Meda Pharma and TETEC. Bioventus, Sanofi, and Zimmer Biomet are lagging well behind the leaders in the European market, vying for a larger stake. There are a slew of additional rivals profiled in this research who sell one or more goods in this category.
iData Research uses its unique market and procedure databases, as well as hospital purchase order data, to supplement its primary and secondary research initiatives in order to properly estimate market shares, units sold, average selling prices, product segments and brands, as well as procedural volumes.